<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles/><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_EX_MR%2FL012286%2F1"><gtr:id>02938EE4-A5E0-42FF-804B-EBB8DA5BB0F5</gtr:id><gtr:title>Bias-adjusted inference in Biostatistics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MC_EX_MR/L012286/1</gtr:grantReference><gtr:abstractText>Advancements in medical practice must be evidence based. For example, new treatments for diseases (such as lung
cancer) must be proven effective before being licensed and, equally, modifiable exposures (such as smoking) must be
reliably linked to adverse health outcomes before public health strategies are implemented. This necessitates the
collection, analysis and interpretation of data. In today's competitive world, time and money are in short supply. Scientists
are therefore under pressure to collect this evidence as efficiently as possible, by making use of existing data sources,
novel trial designs and the latest technology where available. However, failure to understand the process by which data
sources are created can lead to a biased picture of the information they provide, and give rise to poor medical decision
making. Some examples of this now follow:
The size (i.e. the number of patients) and the scope (e.g. the question being asked) of a clinical trial has traditionally been
fixed in advance. However, they are increasingly conducted in a sequential fashion, with less rigid guidelines as to the
direction the trial may take. For example, patients with advanced cancer could participate in a randomised trial, but be
allowed to switch to a new treatment if their initial therapy proves ineffective. Or, patients recruited in the second year of a
trial testing a single therapy at multiple doses, could receive the dose which performed the best in year one. Adaptations
like these mean patients can be afforded a high standard of care in the trial, but at the same time enable effective
treatments to be identified and licenced more quickly. Yet, if the data arising from such trials are simply taken at face value,
they can also systematically over- or under-estimate the true effect of the treatment.
One of the primary goals of Epidemiology is to find the root causes of a disease, so that it can be treated effectively. Ethical
and practical reasons often mean that clinical trials - the best way of testing causal hypotheses - are not always possible.
Epidemiologists then must rely on observational or retrospectively collected data to find these causes. However, strong
correlations seen between a potential risk factor (e.g. alcohol intake) and a medical condition (e.g. high blood pressure) are
no guarantee that alcohol causes high blood pressure, because a separate unobserved factor (e.g. salt intake) may in fact
be a relate to both. This is referred to as `confounding bias'. It is difficult to adjust for the effect of confounding, because
one is never sure that all possible confounders, like salt intake, have been found.
An implicit assumption made when synthesising the results of all the available medical trials addressing a particular
research question, in order to inform future health policy, is that they form a representative and unbiased sample of all
studies conducted. However, it is often only practically feasible to find and include studies that have been published in
academic journals. When scientists cherry-pick their most exciting results to submit for publication, and the journal editors
preferentially publish study results based on their statistical significance they induce `dissemination bias'. The result is a
skewed distribution of findings in the public domain that does not represent the true position in a research field.
My collaborators and I will dedicate our research towards solving these problems. Together we will develop statistical
theory, put it to the test using computer simulation, and then present our results at international conferences for further
critical appraisal. Once we are confident of their worth, we will apply our new methods in the analysis and interpretation of
existing patient data. In the long term our work may influence the way that future scientific studies are designed, reduce
wasted resources in the NHS and, ultimately, benefit the health and wellbeing of</gtr:abstractText><gtr:technicalSummary>My methodological research will be split into three areas of estimation. Please see `Case for Support' for further
clarification.
In Methodology area 1 (G-estimation) I plan to develop:
(1a) Bias-adjusted Structural Mean Models (SMMs) for Mendelian randomisation (MR) analyses using multiple instrumental
variables (IVs) that use genome-wide association study (GWAS) data for IV selection;
(1b) SMMs that can detect and, if necessary, adjust for pleiotropy in MR analyses;
(1c) SMMs that are robust to weak instrument bias in MR analyses;
(1d) Optimal time-dependent weights for the Rank Preserving Structural Failure Time Model (RPSFTM) that provide more
precise G-estimates of the causal effect of treatment in clinical trials of late stage cancer patients;
(1e) RPSFTMs that are valid in the presence of treatment effect heterogeneity.
Objectives (1a)-(1e) will be in conjunction with Professor's Nuala Sheehan, George Davey Smith, Stijn Vansteelandt and Dr
Ian White.
In Methodology area 2 (Minimum variance unbiased estimation) I plan to:
(2a) Extend MVUE methodology from two-stage to multi-stage Adaptive Seamless Designs (ASDs);
(2b) Adapt and apply new MVUE methodology from (2a) to quantify sensitivity, specificity, ROC curve and risk prediction
model parameters in multi-stage trials into diagnostic biomarkers.
Objectives (2a-2b) will be in collaboration with Professor's Ekkehard Glimm and Toby Prevost.
In Methodology area 3 (Shrinkage estimation) I plan to develop:
(3a) Methods of shrinkage estimation for selected treatments in two-stage and multi-stage ASDs;
(3b) A common Empirical Bayesian framework for bias-adjusted meta-analysis in the presence of small study effects.
Objectives (3a-b) will be in conjunction with Professor's Werner Brannath, Sue Todd and Dr Gerta Rucker</gtr:technicalSummary><gtr:fund><gtr:end>2016-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>0</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>We developed a web-based data-visualisation tool for evidence synthesis named the Meta-Analyser. The tool was originally developed from a public outreach exhibit at the 2014 Cambridge Science festival to explain the notation of weighting evidence and of biased evidence to a lay-audience. The meta-analyser is intuitive, because it equates the statistical task of parameter estimation with finding the centre of mass of a system of weights.

The web application can be found at</gtr:description><gtr:id>1D917BFB-F753-4939-860E-469761593EC7</gtr:id><gtr:impact>As part of a joint initiative with the school of Engineering at the University of Bristol, we plan to design and build a fully functioning physical and tangible user interface to visualise the process of weighing evidence and of various modelling choices in Mendelian randomization and evidence synthesis. We will also develop educational and public outreach programmes incorporating the physical model to explain and promote the work of the IEU and the scientific community to the wider public.

This work would not have been possible without development of the web application</gtr:impact><gtr:outcomeId>58c283565fe018.48709697</gtr:outcomeId><gtr:title>Meta-analyser web app</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:url>https://chjackson.shinyapps.io/MetaAnalyser/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E547B733-8AAD-4923-8823-9A5529E7108F</gtr:id><gtr:title>Genome-wide association analyses of sleep disturbance traits identify new loci and highlight shared genetics with neuropsychiatric and metabolic traits.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f201963144dbb8244a138c3fab9d7f13"><gtr:id>f201963144dbb8244a138c3fab9d7f13</gtr:id><gtr:otherNames>Lane JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>58b69908d42920.44488137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B050D07A-7BC0-44CB-AAAB-61B4B8F6E07D</gtr:id><gtr:title>A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>545780422e8199.55306705</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC82FDBD-E675-43F7-881C-A730D35FE7EA</gtr:id><gtr:title>Body mass index and psychiatric disorders: a Mendelian randomization study.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63ddda82c200eef42220f9787d5403fc"><gtr:id>63ddda82c200eef42220f9787d5403fc</gtr:id><gtr:otherNames>Hartwig FP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58b69909dfd8b6.27233354</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>236290AD-8F18-4C87-B467-A148BB499772</gtr:id><gtr:title>Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study.</gtr:title><gtr:parentPublicationTitle>JAMA oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1282d5d2fc80d7756326a54578cb41f8"><gtr:id>1282d5d2fc80d7756326a54578cb41f8</gtr:id><gtr:otherNames>Telomeres Mendelian Randomization Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2374-2437</gtr:issn><gtr:outcomeId>58b699080760f4.30625181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B801A86-9FDB-4BDE-8B31-28686EC30369</gtr:id><gtr:title>An optimal stratified Simon two-stage design.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c73ca5960e9918f43a11542761f8fd5"><gtr:id>4c73ca5960e9918f43a11542761f8fd5</gtr:id><gtr:otherNames>Parashar D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>58b6990a6d9b62.59110091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFC807CA-032A-4CDE-8272-7FFC52A1005B</gtr:id><gtr:title>Palliative treatment for symptomatic malignant pericardial effusion?.</gtr:title><gtr:parentPublicationTitle>Interactive cardiovascular and thoracic surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4896432eb737cacdb634de247fdc3922"><gtr:id>4896432eb737cacdb634de247fdc3922</gtr:id><gtr:otherNames>Jama GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1569-9285</gtr:issn><gtr:outcomeId>54578042d74ef9.50293453</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF8E00FA-12BC-41E7-BB51-10E717142E8A</gtr:id><gtr:title>Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants.</gtr:title><gtr:parentPublicationTitle>Epidemiology (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/056163b112d2b291ecc076d094a1b4e8"><gtr:id>056163b112d2b291ecc076d094a1b4e8</gtr:id><gtr:otherNames>Burgess S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1044-3983</gtr:issn><gtr:outcomeId>58b699089427f8.12648068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E8B9D3C-D1A1-4637-878D-E8C8D65AFF83</gtr:id><gtr:title>A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>58b699098e0025.93955015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F32DC985-8B72-4BD5-9EE9-E27333E7973F</gtr:id><gtr:title>Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials.</gtr:title><gtr:parentPublicationTitle>Biometrical journal. Biometrische Zeitschrift</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0323-3847</gtr:issn><gtr:outcomeId>5457804208ef27.40364607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CA70E2E-6A32-4654-9C0E-3CD272EE2442</gtr:id><gtr:title>Accelerated longitudinal designs: An overview of modelling, power, costs and handling missing data.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ae11a75b026b6f35ad1d7edc2fb8b7d"><gtr:id>1ae11a75b026b6f35ad1d7edc2fb8b7d</gtr:id><gtr:otherNames>Galbraith S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>545780428db361.02276837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9B0902A-DC36-439E-A0F8-AB648919BAEB</gtr:id><gtr:title>Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f4e2610836a71803b87994e3e46760d"><gtr:id>8f4e2610836a71803b87994e3e46760d</gtr:id><gtr:otherNames>Gage SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>58b69909280346.50278772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2200C2B-ABFF-436C-945F-B3694912C795</gtr:id><gtr:title>Empirical Bayes estimation of the selected treatment mean for two-stage drop-the-loser trials: a meta-analytic approach.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>54578041dbd5f2.93615646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>470984D1-5D31-46F5-9AB8-A839EE75BCCB</gtr:id><gtr:title>Accounting for selection and correlation in the analysis of two-stage genome-wide association studies.</gtr:title><gtr:parentPublicationTitle>Biostatistics (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6ede0aadb5e4a65b68f613471edca96"><gtr:id>e6ede0aadb5e4a65b68f613471edca96</gtr:id><gtr:otherNames>Robertson DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1465-4644</gtr:issn><gtr:outcomeId>58b6990aa82559.39267068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22B6F590-8FDF-487B-8B3F-339B819133CE</gtr:id><gtr:title>Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies.</gtr:title><gtr:parentPublicationTitle>The American journal of clinical nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/360a808324aad78098cb2db35a75a186"><gtr:id>360a808324aad78098cb2db35a75a186</gtr:id><gtr:otherNames>Haycock PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9165</gtr:issn><gtr:outcomeId>58b69bc62a6e42.47048827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE11D099-B02A-4BD6-8B20-FCD44433DB38</gtr:id><gtr:title>Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6ede0aadb5e4a65b68f613471edca96"><gtr:id>e6ede0aadb5e4a65b68f613471edca96</gtr:id><gtr:otherNames>Robertson DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>58b6990a290e75.66731745</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F693175E-3D18-45DA-B561-8BE369D1CDDF</gtr:id><gtr:title>Using Mendelian randomization to determine causal effects of maternal pregnancy (intrauterine) exposures on offspring outcomes: Sources of bias and methods for assessing them.</gtr:title><gtr:parentPublicationTitle>Wellcome open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c6a131288567f5723d9a6d6ced956f2"><gtr:id>5c6a131288567f5723d9a6d6ced956f2</gtr:id><gtr:otherNames>Lawlor D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2398-502X</gtr:issn><gtr:outcomeId>58b69908561c49.84553265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CA2BC7C-00E0-4A5C-924F-EE8B08017FFE</gtr:id><gtr:title>A multi-stage drop-the-losers design for multi-arm clinical trials.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b3a7c3073fc54ec79ec58d0024d3b"><gtr:id>667b3a7c3073fc54ec79ec58d0024d3b</gtr:id><gtr:otherNames>Wason J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>544a4c5d272cf0.87597520</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_EX_MR/L012286/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>